Allist(SH:688578)2025-10-28 10:50Financial Performance - The company's operating revenue for Q3 2025 reached ¥1,359,255,073.59, representing a year-on-year increase of 42.03%[4] - The total profit for the period was ¥653,238,072.31, reflecting a growth of 36.39% compared to the same period last year[4] - Net profit attributable to shareholders was ¥564,541,276.71, up 38.77% year-on-year[4] - The basic earnings per share for the quarter was ¥1.25, an increase of 38.89% from the previous year[4] - For the first nine months of 2025, total revenue reached RMB 3.733 billion, reflecting a growth of 47.35% compared to the same period last year; net profit attributable to shareholders was RMB 1.616 billion, an increase of 52.01% year-over-year[13] - Total operating revenue for the first three quarters of 2025 reached ¥3,733,017,652.99, a 47.3% increase from ¥2,533,480,109.53 in the same period of 2024[24] - Net profit for the first three quarters of 2025 was ¥1,615,776,618.13, up 52.1% from ¥1,062,948,077.37 in the previous year[25] - The company reported a basic earnings per share of ¥3.59, compared to ¥2.36 in the same period of 2024, marking a 52.1% increase[25] Research and Development - Research and development expenses totaled ¥124,255,548.96, a decrease of 46.80% compared to the same period last year[5] - Research and development expenses increased to ¥312,825,837.66, representing a 50.5% rise compared to ¥207,670,593.28 in the first three quarters of 2024[24] - The company won the China Patent Gold Award for its innovative technology related to Furmetin, recognizing its contributions to technological innovation and the biopharmaceutical industry[18] Assets and Liabilities - The company's total assets increased by 22.70% year-on-year, reaching ¥7,259,340,818.95[5] - As of September 30, 2025, total assets amounted to RMB 7.259 billion, an increase from RMB 5.916 billion at the end of 2024[20] - The total liabilities as of September 30, 2025, included accounts payable of RMB 84.42 million and employee compensation payable of RMB 247.39 million, reflecting the company's operational commitments[20] - Total liabilities increased to ¥760,534,429.03 from ¥633,318,203.75, reflecting a growth of 20.1%[21] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period was ¥1,730,339,665.78, reflecting a growth of 39.94%[4] - Cash flow from operating activities generated a net amount of ¥1,730,339,665.78, compared to ¥1,236,489,837.49 in the same period last year, indicating a 40% increase[28] - The company's cash and cash equivalents stood at RMB 1.08 billion, compared to RMB 586.99 million at the end of 2024, indicating improved liquidity[20] - Cash and cash equivalents at the end of the period totaled ¥850,508,897.06, an increase from ¥474,698,599.31 in the previous year[30] Product Performance - The company reported a significant increase in sales of its core product, with a notable contribution from the sales of Meletin tablets[9] - The sales revenue of the drug Furmetin (甲磺酸伏美替尼片) steadily increased, enhancing patient accessibility and expanding the beneficiary group for lung cancer patients[14] - The marketing team is actively promoting the RET inhibitor Pralsetinib (普吉华®), which has received approval for domestic production, expected to transition from imported to locally produced products starting in 2026[14] - In July 2025, the drug application for Furmetin for treating advanced/metastatic NSCLC with EGFR 20 insertion mutation was accepted by CDE and included in the priority review list[15] - The Phase II study results for Furmetin showed an objective response rate (ORR) of 44.3% and a median overall survival (OS) of 21.2 months, indicating promising clinical efficacy and good safety profile[17]